FGF21 and its Relationship with Inflammatory and Metabolic Parameters in HIV Patients after Antiretroviral Treatment

Author(s): Alan Joel Ruiz-Padilla, Yeniley Ruiz-Noa*, Lorena del Rocio Ibarra-Reynoso, Maria-Luisa Lazo-de-la-Vega-Monroy, Angel Josabad Alonso-Castro, Mauricio Sánchez-Barajas, Rosa Margarita Alvarez-Alvarez, Mónica del Carmen Preciado-Puga

Journal Name: Current HIV Research
HIV and Viral Immune Diseases

Volume 18 , Issue 5 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Fibroblast Growth Factor 21 (FGF21) serum levels are associated with insulin resistance and metabolic syndrome in HIV patients.

Objective: To quantify FGF21 levels in HIV patients using antiretroviral therapy (ART) and to analyze a possible association between serum FGF21 levels and lipid profile, levels of proinflammatory cytokines, and atherogenic risk factors.

Materials and Methods: Twenty patients with HIV infection, who received ART in a scheme consisting of Tenofovir/Emtricitabine+Lopinavir/Ritonavir, were enrolled in this study. The serum levels of FGF21, inflammatory parameters (IL-6 and IL-1β), glucose, cholesterol, triglycerides, and insulin were determined at baseline and after 36 weeks of treatment. The homeostatic model assessment for insulin resistance (HOMA-IR) and the atherogenic risk factor were also calculated.

Results: After 36 weeks, serum FGF21 levels decreased significantly (p=0.011), whereas IL-6 levels (r=0.821, p=0.0001) and the CD4+ T cell count (r=0.446, p=0.048), showed a positive correlation with the decrease in FGF21 levels. There was an increase in total cholesterol (r=-0.483, p=0.031), LDL (r=-0.496, p=0.026), VLDL (r=-0.320, p=0.045), and the atherogenic index factor (r=-0.539, p=0.014), these values showed a negative correlation with FGF21 levels.

Conclusion: The decrease of serum FGF21 levels due to ART is associated with the alteration in lipid profile and an increased risk for cardiovascular diseases. These variations are predictors of inflammatory status in HIV patients using antiretroviral therapy.

Keywords: Antiretroviral therapy, FGF21, human immunodeficiency virus, IL-6, inflammatory and metabolic parameters, AIP.

[1]
SIDA. Vigilancia Epidemiológica de casos de VIH/SIDA en México Registro Nacional de Casos de SIDA Actualización al Cierre de. 2019. Available at: http://www.sidastudi.org/es/registro/a53b7fb370aee4520170af8b2ee90013
[2]
Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304(3): 321-33.
[http://dx.doi.org/10.1001/jama.2010.1004] [PMID: 20639566]
[3]
Murphy RL, da Silva BA, Hicks CB, et al. Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients. HIV Clin Trials 2008; 9(1): 1-10.
[http://dx.doi.org/10.1310/hct0901-1] [PMID: 18215977]
[4]
Stockdale AJ, Saunders MJ, Boyd MA, et al. Effectiveness of protease inhibitor/nucleos(t)ide reverse transcriptase inhibitor based second-line antiretroviral therapy for the treatment of human immunodeficiency virus type 1 infection in sub-saharan Africa: a systematic review and meta-analysis. Clin Infect Dis 2018; 66(12): 1846-57.
[http://dx.doi.org/10.1093/cid/cix1108] [PMID: 29272346]
[5]
Thenin-Houssier S, Valente ST. HIV-1 Capsid Inhibitors as Antiretroviral Agents. Curr HIV Res 2016; 14(3): 270-82.
[http://dx.doi.org/10.2174/1570162X14999160224103555] [PMID: 26957201]
[6]
Sham HL, Betebenner DA, Herrin T, et al. Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir). Bioorg Med Chem Lett 2001; 11(11): 1351-3.
[http://dx.doi.org/10.1016/S0960-894X(01)00243-8] [PMID: 11378352]
[7]
Molina JM, Andrade-Villanueva J, Echevarria J, et al. CASTLE Study Team. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48-week efficacy and safety results of the CASTLE study. Lancet 2008; 372(9639): 646-55.
[http://dx.doi.org/10.1016/S0140-6736(08)61081-8] [PMID: 18722869]
[8]
Pau AK, George JM. Antiretroviral therapy: current drugs. Infect Dis Clin North Am 2014; 28(3): 371-402.
[http://dx.doi.org/10.1016/j.idc.2014.06.001] [PMID: 25151562]
[9]
Abah IO, Ncube NBQ, Bradley HA. AgbaJi OO, Kanki P. Antiretroviral Therapy-associated Adverse Drug Reactions and their Effects on Virologic Failure- A Retrospective Cohort Study in Nigeria. Curr HIV Res 2018; 16(6): 436-46.
[http://dx.doi.org/10.2174/1389450120666190214144609] [PMID: 30767743]
[10]
Manfredi R, Sabbatani S. Serious, multi-organ hypersensitivity to lopinavir alone, involving cutaneous-mucous rash, and myeloid, liver, and kidney function. AIDS 2006; 20(18): 2399-400.
[http://dx.doi.org/10.1097/QAD.0b013e328010f212] [PMID: 17117031]
[11]
Jain MK. Drug-induced liver injury associated with HIV medications. Clin Liver Dis 2007; 11(3): 615-39.
[http://dx.doi.org/10.1016/j.cld.2007.06.008] [PMID: 17723923]
[12]
Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004; 38(Suppl. 2): S90-7.
[http://dx.doi.org/10.1086/381444] [PMID: 14986280]
[13]
Grand M, Bia D, Diaz A. Cardiovascular Risk Assessment in People Living With HIV: A Systematic Review and Meta-Analysis of Real-Life Data. Curr HIV Res 2020; 18(1): 5-18.
[http://dx.doi.org/10.2174/1570162X17666191212091618] [PMID: 31830884]
[14]
Palios J, Kadoglou NP, Lampropoulos S. The pathophysiology of HIV-/HAART-related metabolic syndrome leading to cardiovascular disorders: the emerging role of adipokines. Exp Diabetes Res 2012; 2012: 103063.
[http://dx.doi.org/10.1155/2012/103063] [PMID: 22203832]
[15]
Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol 2013; 119: 51-83.
[http://dx.doi.org/10.1016/B978-0-12-407707-2.00002-3] [PMID: 23886064]
[16]
de Gaetano Donati K, Rabagliati R, Iacoviello L, Cauda R. HIV infection, HAART, and endothelial adhesion molecules: current perspectives. Lancet Infect Dis 2004; 4(4): 213-22.
[http://dx.doi.org/10.1016/S1473-3099(04)00971-5] [PMID: 15050939]
[17]
Crum-Cianflone NF, Weekes J, Bavaro M. Review: thromboses among HIV-infected patients during the highly active antiretroviral therapy era. AIDS Patient Care STDS 2008; 22(10): 771-8.
[http://dx.doi.org/10.1089/apc.2008.0010] [PMID: 18783326]
[18]
Gori E, Mduluza T, Nyagura M, Stray-Pedersen B, Gomo ZA. Inflammation-modulating cytokine profile and lipid interaction in HIV-related risk factors for cardiovascular diseases. Ther Clin Risk Manag 2016; 12: 1659-66.
[http://dx.doi.org/10.2147/TCRM.S117980] [PMID: 27956833]
[19]
Schlein C, Talukdar S, Heine M, et al. FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues. Cell Metab 2016; 23(3): 441-53.
[http://dx.doi.org/10.1016/j.cmet.2016.01.006] [PMID: 26853749]
[20]
Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115(6): 1627-35.
[http://dx.doi.org/10.1172/JCI23606] [PMID: 15902306]
[21]
Fisher FM, Maratos-Flier E. Understanding the Physiology of FGF21. Annu Rev Physiol 2016; 78: 223-41.
[http://dx.doi.org/10.1146/annurev-physiol-021115-105339] [PMID: 26654352]
[22]
Camporez JP, Jornayvaz FR, Petersen MC, et al. Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology 2013; 154(9): 3099-109.
[http://dx.doi.org/10.1210/en.2013-1191] [PMID: 23766126]
[23]
Zhang Y, Lei T, Huang JF, et al. The link between fibroblast growth factor 21 and sterol regulatory element binding protein 1c during lipogenesis in hepatocytes. Mol Cell Endocrinol 2011; 342(1-2): 41-7.
[http://dx.doi.org/10.1016/j.mce.2011.05.003] [PMID: 21664250]
[24]
Dushay J, Chui PC, Gopalakrishnan GS, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010; 139(2): 456-63.
[http://dx.doi.org/10.1053/j.gastro.2010.04.054] [PMID: 20451522]
[25]
Li H, Fang Q, Gao F, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 2010; 53(5): 934-40.
[http://dx.doi.org/10.1016/j.jhep.2010.05.018] [PMID: 20675007]
[26]
Bao L, Yin J, Gao W, Wang Q, Yao W, Gao X. A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway. Br J Pharmacol 2018; 175(16): 3379-93.
[http://dx.doi.org/10.1111/bph.14383] [PMID: 29859019]
[27]
Fisher FM, Chui PC, Nasser IA, et al. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology 2014; 147(5): 1073-83.
[http://dx.doi.org/10.1053/j.gastro.2014.07.044]
[28]
Kim SH, Kim KH, Kim HK, et al. Fibroblast growth factor 21 participates in adaptation to endoplasmic reticulum stress and attenuates obesity-induced hepatic metabolic stress. Diabetologia 2015; 58(4): 809-18.
[http://dx.doi.org/10.1007/s00125-014-3475-6] [PMID: 25537833]
[29]
Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, Defronzo RA, Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009; 32(8): 1542-6.
[http://dx.doi.org/10.2337/dc09-0684] [PMID: 19487637]
[30]
Pan Y, Wang B, Zheng J, et al. Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling-dependent manner. J Cell Mol Med 2019; 23(2): 1059-71.
[http://dx.doi.org/10.1111/jcmm.14007] [PMID: 30461198]
[31]
Lin Z, Wu Z, Yin X, et al. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One 2010; 5(12): e15534.
[http://dx.doi.org/10.1371/journal.pone.0015534] [PMID: 21206918]
[32]
Payne BA, Price DA, Chinnery PF. Elevated serum fibroblast growth factor 21 levels correlate with immune recovery but not mitochondrial dysfunction in HIV infection. AIDS Res Ther 2013; 10(1): 27.
[http://dx.doi.org/10.1186/1742-6405-10-27] [PMID: 24252301]
[33]
Gallego-Escuredo JM, Lamarca MK, Villarroya J, et al. High FGF21 levels are associated with altered bone homeostasis in HIV-1-infected patients. Metabolism 2017; 71: 163-70.
[http://dx.doi.org/10.1016/j.metabol.2017.03.014] [PMID: 28521869]
[34]
Moure R, Domingo P, Villarroya J, et al. Reciprocal Effects of Antiretroviral Drugs Used To Treat HIV Infection on the Fibroblast Growth Factor 21/β-Klotho System. Antimicrob Agents Chemother 2018; 62(6): e00029-18.
[http://dx.doi.org/10.1128/AAC.00029-18] [PMID: 29661866]
[35]
Eckard AR, Hughes HY, Hagood NL, et al. Fibroblast Growth Factor 21 Is Elevated in HIV and Associated With Interleukin-6. J Acquir Immune Defic Syndr 2020; 83(5): e30-3.
[http://dx.doi.org/10.1097/QAI.0000000000002285] [PMID: 31913998]
[36]
Domingo P, Gallego-Escuredo JM, Domingo JC, et al. Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients. AIDS 2010; 24(17): 2629-37.
[http://dx.doi.org/10.1097/QAD.0b013e3283400088] [PMID: 20935553]
[37]
Gallego-Escuredo JM, Domingo P, Gutiérrez Mdel M, et al. Reduced levels of serum FGF19 and impaired expression of receptors for endocrine FGFs in adipose tissue from HIV-infected patients. J Acquir Immune Defic Syndr 2012; 61(5): 527-34.
[http://dx.doi.org/10.1097/QAI.0b013e318271c2c7] [PMID: 23187887]
[38]
Yu Y, Li S, Liu Y, et al. Fibroblast growth factor 21 (FGF21) ameliorates collagen-induced arthritis through modulating oxidative stress and suppressing nuclear factor-kappa B pathway. Int Immunopharmacol 2015; 25(1): 74-82.
[http://dx.doi.org/10.1016/j.intimp.2015.01.005] [PMID: 25601498]
[39]
Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007; 5(6): 415-25.
[http://dx.doi.org/10.1016/j.cmet.2007.05.003] [PMID: 17550777]
[40]
De Sousa-Coelho AL, Marrero PF, Haro D. Activating transcription factor 4-dependent induction of FGF21 during amino acid deprivation. Biochem J 2012; 443(1): 165-71.
[http://dx.doi.org/10.1042/BJ20111748] [PMID: 22233381]
[41]
Xu P, Zhang Y, Liu Y, et al. Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways. Toxicol Appl Pharmacol 2016; 290: 43-53.
[http://dx.doi.org/10.1016/j.taap.2015.11.012] [PMID: 26592322]
[42]
Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007; 5(6): 426-37.
[http://dx.doi.org/10.1016/j.cmet.2007.05.002] [PMID: 17550778]
[43]
Feingold KR, Grunfeld C, Heuer JG, et al. FGF21 is increased by inflammatory stimuli and protects leptin-deficient ob/ob mice from the toxicity of sepsis. Endocrinology 2012; 153(6): 2689-700.
[http://dx.doi.org/10.1210/en.2011-1496] [PMID: 22474187]
[44]
Yu Y, He J, Li S, et al. Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-κB signaling pathway. Int Immunopharmacol 2016; 38: 144-52.
[http://dx.doi.org/10.1016/j.intimp.2016.05.026] [PMID: 27276443]
[45]
Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem 2001; 34(7): 583-8.
[http://dx.doi.org/10.1016/S0009-9120(01)00263-6] [PMID: 11738396]
[46]
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28(7): 412-9.
[http://dx.doi.org/10.1007/BF00280883] [PMID: 3899825]
[47]
Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74(5): 1045-52.
[PMID: 1373735]
[48]
Lake JE, Currier JS. Metabolic disease in HIV infection. Lancet Infect Dis 2013; 13(11): 964-75.
[http://dx.doi.org/10.1016/S1473-3099(13)70271-8] [PMID: 24156897]
[49]
Friis-Møller N, Weber R, Reiss P, et al. DAD study group Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17(8): 1179-93.
[http://dx.doi.org/10.1097/00002030-200305230-00010] [PMID: 12819520]
[50]
Aurpibul L, Namwongprom S, Sudjaritruk T, Ounjaijean S. Metabolic syndrome, biochemical markers, and body composition in youth living with perinatal HIV infection on antiretroviral treatment. PLoS One 2020; 15(3)e0230707
[http://dx.doi.org/10.1371/journal.pone.0230707] [PMID: 32226033]
[51]
Dai L, Liu A, Zhang H, et al. Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study. Curr HIV Res 2019; 17(5): 324-34.
[http://dx.doi.org/10.2174/1570162X17666191025115508] [PMID: 31654514]
[52]
Phalane E, Fourie CM, Mels CM, Schutte AE. A 10-year follow-up study of demographic and cardiometabolic factors in HIV-infected South Africans. Cardiovasc J Afr 2019; 30: 1-5.
[http://dx.doi.org/10.5830/CVJA-2019-034] [PMID: 31469383]
[53]
Agu CE, Uchendu IK, Nsonwu AC, Okwuosa CN, Achukwu PU. Prevalence and associated risk factors of peripheral artery disease in virologically suppressed HIV-infected individuals on antiretroviral therapy in Kwara state, Nigeria: a cross sectional study. BMC Public Health 2019; 19(1): 1143.
[http://dx.doi.org/10.1186/s12889-019-7496-4] [PMID: 31429736]
[54]
Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352(1): 48-62.
[http://dx.doi.org/10.1056/NEJMra041811] [PMID: 15635112]
[55]
Rodríguez-Gallego E, Gómez J, Domingo P, et al. CORIS-NADES events Study Group. Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy. Atherosclerosis 2018; 273: 28-36.
[http://dx.doi.org/10.1016/j.atherosclerosis.2018.04.008] [PMID: 29677628]
[56]
Augustemak de Lima LR, Petroski EL, Moreno YMF, et al. Dyslipidemia, chronic inflammation, and subclinical atherosclerosis in children and adolescents infected with HIV: The PositHIVe Health Study. PLoS One 2018; 13(1): e0190785.
[http://dx.doi.org/10.1371/journal.pone.0190785] [PMID: 29320547]
[57]
Sacilotto LB, Pereira PCM, Manechini JPV, Papini SJ. Body Composition and Metabolic Syndrome Components on Lipodystrophy Different Subtypes Associated with HIV. J Nutr Metab 2017; 2017: 8260867.
[http://dx.doi.org/10.1155/2017/8260867] [PMID: 28540084]
[58]
Jamieson L, Evans D, Brennan AT, et al. Changes in elevated cholesterol in the era of tenofovir in South Africa: risk factors, clinical management and outcomes. HIV Med 2017; 18(8): 595-603.
[http://dx.doi.org/10.1111/hiv.12495] [PMID: 28332270]
[59]
Sabin CA, Worm SW, Weber R, et al. D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371(9622): 1417-26.
[http://dx.doi.org/10.1016/S0140-6736(08)60423-7] [PMID: 18387667]
[60]
Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial infarction: findings of an FDA metaanalysis. J Acquir Immune Defic Syndr 2012; 61(4): 441-7.
[http://dx.doi.org/10.1097/QAI.0b013e31826f993c] [PMID: 22932321]
[61]
Keipert S, Lutter D, Schroeder BO, et al. Endogenous FGF21-signaling controls paradoxical obesity resistance of UCP1-deficient mice. Nat Commun 2020; 11(1): 624.
[http://dx.doi.org/10.1038/s41467-019-14069-2] [PMID: 32005798]
[62]
Xie T, So WY, Li XY, Leung PS. Fibroblast growth factor 21 protects against lipotoxicity-induced pancreatic β-cell dysfunction via regulation of AMPK signaling and lipid metabolism. Clin Sci (Lond) 2019; 133(19): 2029-44.
[http://dx.doi.org/10.1042/CS20190093] [PMID: 31654570]
[63]
Gao RY, Hsu BG, Wu DA, Hou JS, Chen MC. Serum Fibroblast Growth Factor 21 Levels Are Positively Associated with Metabolic Syndrome in Patients with Type 2 Diabetes. Int J Endocrinol 2019; 2019: 5163245.
[http://dx.doi.org/10.1155/2019/5163245] [PMID: 31582974]
[64]
Su X, Kong Y, Peng D. Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease. Clin Chim Acta 2019; 498: 30-7.
[http://dx.doi.org/10.1016/j.cca.2019.08.005] [PMID: 31419414]
[65]
Mutsnaini L, Kim CS, Kim J, et al. Fibroblast growth factor 21 deficiency aggravates obesity-induced hypothalamic inflammation and impairs thermogenic response. Inflamm Res 2019; 68(5): 351-8.
[http://dx.doi.org/10.1007/s00011-019-01222-2] [PMID: 30863887]
[66]
Li H, Wu G, Fang Q, et al. Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat. Nat Commun 2018; 9(1): 272.
[http://dx.doi.org/10.1038/s41467-017-02677-9] [PMID: 29348470]
[67]
Cheng X, Zhu B, Jiang F, Fan H. Serum FGF-21 levels in type 2 diabetic patients. Endocr Res 2011; 36(4): 142-8.
[http://dx.doi.org/10.3109/07435800.2011.558550] [PMID: 21973233]
[68]
Huang Z, Xu A, Cheung BMY. The Potential Role of Fibroblast Growth Factor 21 in Lipid Metabolism and Hypertension. Curr Hypertens Rep 2017; 19(4): 28.
[http://dx.doi.org/10.1007/s11906-017-0730-5] [PMID: 28337713]
[69]
Kralisch S, Tönjes A, Krause K, et al. Fibroblast growth factor-21 serum concentrations are associated with metabolic and hepatic markers in humans. J Endocrinol 2013; 216(2): 135-43.
[http://dx.doi.org/10.1530/JOE-12-0367] [PMID: 23129782]
[70]
Wang YS, Ye J, Cao YH, et al. Increased serum/plasma fibroblast growth factor 21 in type 2 diabetes mellitus: a systematic review and meta-analysis. Postgrad Med J 2019; 95(1121): 134-9.
[http://dx.doi.org/10.1136/postgradmedj-2018-136002] [PMID: 30918117]
[71]
Baek J, Nam HK, Rhie YJ, Lee KH. Serum FGF21 Levels in Obese Korean Children and Adolescents. J Obes Metab Syndr 2017; 26(3): 204-9.
[http://dx.doi.org/10.7570/jomes.2017.26.3.204] [PMID: 31089518]
[72]
Jin QR, Bando Y, Miyawaki K, et al. Correlation of fibroblast growth factor 21 serum levels with metabolic parameters in Japanese subjects. J Med Invest 2014; 61(1-2): 28-34.
[http://dx.doi.org/10.2152/jmi.61.28] [PMID: 24705745]
[73]
Chen L, Jiang M, Xin Y, et al. [Role and mechanism of action of fibroblast growth factor-21 in reducing triglyceride in nonalcoholic fatty liver disease] Zhonghua Gan Zang Bing Za Zhi 2016; 24(2): 102-7.
[PMID: 26983476]
[74]
Kotulák T, Drápalová J, Kopecký P, et al. Increased circulating and epicardial adipose tissue mRNA expression of fibroblast growth factor-21 after cardiac surgery: possible role in postoperative inflammatory response and insulin resistance. Physiol Res 2011; 60(5): 757-67.
[http://dx.doi.org/10.33549/physiolres.932134] [PMID: 21812521]
[75]
Kelesidis T, Kendall MA, Yang OO, Hodis H, Currier JS. Perturbations of circulating levels of RANKL-osteoprotegerin axis in relation to lipids and progression of atherosclerosis in HIV infected and -uninfected adults: ACTG NWCS 332/A5078 Study. AIDS Res Hum Retroviruses 2013; 29(6): 938-48.
[http://dx.doi.org/10.1089/aid.2012.0305] [PMID: 23351153]
[76]
Baker JV, Neuhaus J, Duprez D, et al. INSIGHT SMART Study Group. Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy. AIDS 2011; 25(17): 2133-42.
[http://dx.doi.org/10.1097/QAD.0b013e32834be088] [PMID: 21857489]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 5
Year: 2020
Page: [308 - 314]
Pages: 7
DOI: 10.2174/1570162X18666200719235625
Price: $65

Article Metrics

PDF: 22
HTML: 3
PRC: 1